by The global Mutation Detection Kits In Genome Editing market size is expected to be worth around US$ 565.1 million by 2030, according to a new report by Vision Research Reports.
The global Mutation Detection Kits In Genome Editing market size was valued at US$ 226.9 million in 2020 and is anticipated to grow at a CAGR of 18.3% during forecast period 2021 to 2030.
Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/39057
Growth Factors
Widespread usage of genome editing techniques, coupled with the increasing investment flow in the development of mutation detection kits to accelerate the adoption of genome editing methodologies, has majorly driven the growth of the market. The discovery of polymorphisms and unknown mutations in genome sequences is a significant aspect of widespread research and clinical areas, including pharmacogenetics, disease treatment, and reverse genetics study in model organisms. This has driven the adoption of mutation detection kits in genome manipulation space, in turn, propelling the market growth throughout the forecast period.
Report Coverage
| Report Scope | Details |
| Market Size | US$ 565.1 million by 2030 |
| Growth Rate | CAGR of 18.3% From 2021 to 2030 |
| Largest Market | North America |
| Base Year | 2021 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Technology by application, End-use |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Mentioned | Thermo Fisher Scientific; Takara Bio Inc.; Integrated DNA Technologies, Inc.; Lucigen; Promega Corporation; GenScript; Synthego; New England Biolabs; Applied Biological Materials, Inc. (abm); Bio-Rad Laboratories; AddGene; Biovision Inc. |
By Technology By Application Analysis
CRISPR/Cas9 technology dominated the market in 2020 with a share of over 40.0%. The emergence of this technology has revolutionized the field of medical diagnostics and research on genetic testing.
The researchers combined CRISPR with graphene electronic transistors in this new device to detect specific gene mutations in a very small timeframe. This device, named CRISPR-Chip, can diagnose genetic diseases in less time and can also be used for the evaluation of the accuracy of genome-editing technologies.
Limitations associated with the CRISPR technique have resulted in increased applications of TALEN technology in some genomic regions that are hard to edit. A study was published in January 2021, which stated that for compact DNA studies, TALEN was found to be a more suitable tool.
By End-use Analysis
Academic and government research institutes dominated the market with a revenue share of over 50.0% in 2020 owing to the ongoing clinical trials, a rise in the preference of personalized medicine, and R&D activities in clinical diagnostics. Moreover, the outbreak of COVID-19 has served as a catalyst for market expansion.
Several research institutes across the globe are actively involved in conducting studies to evaluate the use of various genome editing technologies in mutation detection.
The increasing involvement of biotechnology and pharmaceutical companies is also anticipated to significantly contribute to market growth.
By Regional Analysis
North America dominated the market and accounted for a revenue share of over 35.0% in 2020. This growth in the region can be attributed to the presence of a substantial number of market players, high R&D investments, and continuous technological developments by key players.
Asia Pacific is likely to witness the fastest growth over the forecast period. China was the first country that has successfully transferred genetically modified cells into human cells, to treat lung cancer and boost immunity.
Key Players
- Thermo Fisher Scientific
- Takara Bio Inc.
- Integrated DNA Technologies, Inc.
- Lucigen
- Promega Corporation
- GenScript
- Synthego
- New England Biolabs
- Applied Biological Materials, Inc. (abm)
- Bio-Rad Laboratories
- AddGene
- Biovision Inc.
Market Segmentation
- Technology by Application
- CRISPR/Cas9
- Genetically Modified Organisms (GMO) Analysis
- Disease Genotyping
- Typing of Transgenic Plants
- Therapy Development
- Epigenetic Editing
- ZFN
- Genetically Modified Organisms (GMO) Analysis
- Disease Genotyping
- Typing of Transgenic Plants
- Therapy Development
- Epigenetic Editing
- TALENs/MegaTALs
- Genetically Modified Organisms (GMO) Analysis
- Disease Genotyping
- Typing Of Transgenic Plants
- Therapy Development
- Epigenetic Editing
- Meganucleases
- Genetically Modified Organisms (GMO) Analysis
- Disease Genotyping
- Typing of Transgenic Plants
- Therapy Development
- Epigenetic Editing
- Others
- CRISPR/Cas9
- By End-use
- Biotechnology and Pharmaceutical Companies
- Academic and Government Research Institutes
- Contract Research Organizations
- Regional
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Asia Pacific
- Japan
- China
- India
- South Korea
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- South Africa
- Saudi Arabia
- North America
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Mutation Detection Kits In Genome Editing Market, By Technology by Application
7.1. Mutation Detection Kits In Genome Editing Market, by Technology by Application, 2021-2030
7.1.1. CRISPR/Cas9
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. ZFN
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. TALENs/MegaTALs
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Meganucleases
7.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Mutation Detection Kits In Genome Editing Market, By End-use
8.1. Mutation Detection Kits In Genome Editing Market, by End-use, 2021-2030
8.1.1. Biotechnology and Pharmaceutical Companies
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Academic and Government Research Institutes
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Contract Research Organizations
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Mutation Detection Kits In Genome Editing Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.1.2. Market Revenue and Forecast, by End-use (2017-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.1.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.1.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.2.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.2.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.2.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.2.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.2.6.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.3.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.3.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.3.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.3.6.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.4.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.4.4.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.4.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.4.6.2. Market Revenue and Forecast, by End-use (2017-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.5.2. Market Revenue and Forecast, by End-use (2017-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.5.3.2. Market Revenue and Forecast, by End-use (2017-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Technology by Application (2017-2030)
9.5.4.2. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 10. Company Profiles
10.1. Thermo Fisher Scientific
10.1.1. Company Overview
10.1.2. Technology by Application Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Takara Bio Inc.
10.2.1. Company Overview
10.2.2. Technology by Application Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Integrated DNA Technologies, Inc.
10.3.1. Company Overview
10.3.2. Technology by Application Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Lucigen
10.4.1. Company Overview
10.4.2. Technology by Application Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Promega Corporation
10.5.1. Company Overview
10.5.2. Technology by Application Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. GenScript
10.6.1. Company Overview
10.6.2. Technology by Application Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Synthego
10.7.1. Company Overview
10.7.2. Technology by Application Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. New England Biolabs
10.8.1. Company Overview
10.8.2. Technology by Application Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. Applied Biological Materials, Inc. (abm)
10.9.1. Company Overview
10.9.2. Technology by Application Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Bio-Rad Laboratories
10.10.1. Company Overview
10.10.2. Technology by Application Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/39057
Contact Us:
Vision Research Reports
Call: +1 9197 992 333
